Project

MIC-1

A randomized pilot study on the impact of a modified Mediterranean diet (DMM) on the intestinal microbiota and clinical outcome in patients with colorectal cancer undergoing active medical oncology treatment
Application Areas
Research Areas
Research Lines
Staff
WEBSITE

ITB Principal Investigator

Name

A randomized pilot study on the impact of a modified Mediterranean diet (DMM) on the intestinal microbiota and clinical outcome in patients with colorectal cancer undergoing active medical oncology treatment

Acronym

MIC-1

Location

Segrate

Start Date

2024

End Date

2026

Funder

ASST-BRIANZA

Partners

ASST BRIANZA UniMIB Policlinico Umberto I Roma

MIC-1 aims to investigate how precision nutrition can enhance Gut Microbiota (GM) resilience in patients with metastatic colorectal cancer (mCRC) improving tolerance and clinical outcomes to chemotherapy by an innovative translational approach combining Omics, an in vitro simulator of the gastrointestinal tract (SHIME®) and ex vivo patient-derived intestinal organoids. In detail, MIC-1 aims: 1) to profile GM during oncological treatment and nutritional interventions for identification of microbial, metabolic, and functional signatures linked to resilience and response (Omics), (2) to discover GM-derived compounds useful as biomarkers for monitoring therapy efficacy and disease progression, (3) to study GM-host interactions at the cellular and molecular level for elucidating mechanisms by which GM adapts or recovers (organoids-Omics), 4) test GM restoration strategies in vitro (SHIME).
  • The Effects of a Modified Mediterranean Diet on Gut Microbiota and Chemotherapy Side Effects in Patients With Metastatic Colorectal Cancer Undergoing First-Line Chemotherapy With or Without Either Antiepidermal Growth Factor Receptor or Antivascular Endothelial Growth Factor Agent: Protocol for a Randomized Pilot Study in Italy. – DOI